Financial Analysis: Aquestive Therapeutics Inc (AQST)’s Ratios Unveil Key Insights

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

As of close of business last night, Aquestive Therapeutics Inc’s stock clocked out at $3.07, up 6.23% from its previous closing price of $2.89. In other words, the price has increased by $6.23 from its previous closing price. On the day, 1.05 million shares were traded. AQST stock price reached its highest trading level at $3.075 during the session, while it also had its lowest trading level at $2.89.

Ratios:

To gain a deeper understanding of AQST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.91 and its Current Ratio is at 6.37.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on December 17, 2024, initiated with a Overweight rating and assigned the stock a target price of $17.

On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.

On April 11, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.Piper Sandler initiated its Overweight rating on April 11, 2024, with a $10 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 26 ’24 when Jung Cassie sold 44 shares for $4.87 per share. The transaction valued at 214 led to the insider holds 0 shares of the business.

Schobel Alexander Mark sold 50,000 shares of AQST for $300,000 on Mar 15 ’24. The Chief Innovation/Tech Officer now owns 984,476 shares after completing the transaction at $6.00 per share. On Mar 08 ’24, another insider, Schobel Alexander Mark, who serves as the Chief Innovation/Tech Officer of the company, sold 25,000 shares for $5.19 each. As a result, the insider received 129,685 and left with 1,040,371 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 279917056 and an Enterprise Value of 238893056. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.75. Its current Enterprise Value per Revenue stands at 4.056 whereas that against EBITDA is -11.922.

Stock Price History:

The Beta on a monthly basis for AQST is 2.76, which has changed by 0.094697 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $6.23, while it has fallen to a 52-week low of $2.24. The 50-Day Moving Average of the stock is -16.38%, while the 200-Day Moving Average is calculated to be -20.38%.

Shares Statistics:

It appears that AQST traded 1.56M shares on average per day over the past three months and 1162460 shares per day over the past ten days. A total of 91.18M shares are outstanding, with a floating share count of 77.61M. Insiders hold about 14.88% of the company’s shares, while institutions hold 46.31% stake in the company. Shares short for AQST as of 1736899200 were 11788486 with a Short Ratio of 7.58, compared to 1734048000 on 9653937. Therefore, it implies a Short% of Shares Outstanding of 11788486 and a Short% of Float of 15.479999999999999.

Earnings Estimates

The current rating of Aquestive Therapeutics Inc (AQST) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.16.

Analysts are recommending an EPS of between -$0.33 and -$0.5 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.54, with 4.0 analysts recommending between -$0.44 and -$0.67.

Revenue Estimates

In the current quarter, 9 analysts expect revenue to total $13.11M. It ranges from a high estimate of $15.6M to a low estimate of $11.4M. As of the current estimate, Aquestive Therapeutics Inc’s year-ago sales were $13.21MFor the next quarter, 9 analysts are estimating revenue of $12.9M. There is a high estimate of $14.1M for the next quarter, whereas the lowest estimate is $12M.

A total of 9 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $61.3M, while the lowest revenue estimate was $47M, resulting in an average revenue estimate of $57.5M. In the same quarter a year ago, actual revenue was $50.58MBased on 9 analysts’ estimates, the company’s revenue will be $52.97M in the next fiscal year. The high estimate is $62M and the low estimate is $42.3M.

Most Popular